Table 1

Characteristics of the study sample and proportions and prevalence rate ratios of seropositivity and vaccination

	No. of participants	No. of seropositive	No. of vaccinated participants	Model of antibodies of any origin (n=22 130)			Model of propensity to vaccination (n=22 130)			Model of antibodies in unvaccinated participants (n=7647)
	No. of participants	No. of seropositive	No. of vaccinated participants	% of seropositive	PRR (95% CI)	P value	% of vaccinated	PRR (95% CI)	P value	No. of participants	% of seropositive	PRR (95% CI)	P value
Sex
Female	13 824	12 067	8844	87.29	1.00	–	63.98	1.00	–	4980	67.25	1.00	–
Male	8306	7282	5639	87.67	0.99	0.012	67.89	1.05	<0.001	2667	65.47	0.95	<0.001
Age groups (years)
18–29	1491	1202	770	80.62	1.00	–	51.64	1.00	–	721	61.72	1.00	–
30–39	2774	2275	1534	82.01	1.02	0.215	55.30	1.03	0.420	1240	61.05	0.97	0.338
40–49	6700	5725	4177	85.45	1.01	0.194	62.34	1.17	<0.001	2523	64.05	0.97	0.226
50–59	6049	5405	4061	89.35	1.03	0.003	67.14	1.23	<0.001	1988	70.32	1.04	0.170
60+	5116	4742	3941	92.69	1.05	<0.001	77.03	1.37	<0.001	1175	74.81	1.09	0.001
Education
Basic	1952	1744	1295	89.34	1.00	–	66.34	1.00	–	657	70.02	1.00	–
Medium	8024	7119	5348	88.72	1.00	0.972	66.65	1.02	0.275	2676	69.21	1.02	0.337
High	7544	6689	5223	88.67	1.00	0.890	69.23	1.08	<0.001	2321	65.75	1.02	0.394
Missing	4610	3797	2617	82.36	0.97	0.003	56.77	0.87	<0.001	1993	63.07	1.00	0.923
COVID-19 in history
Seronegative	11 352	8935	7882	78.71	1.00	–	69.43	1.00	–	3470	36.54	1.00	–
Seropositive— no symptoms	5597	5374	3458	96.02	1.28	<0.001	61.78	0.75	<0.001	2139	90.04	3.45	<0.001
Seropositive— with symptoms	5181	5040	3143	97.28	1.32	<0.001	60.66	0.78	<0.001	2038	93.28	3.58	<0.001
BMI
<18.5	256	197	134	76.95	1.00	–	52.34	1.00	–	122	52.46	1.00	–
18.5–24.9	8192	6964	5038	85.01	1.04	0.127	61.50	1.09	0.141	3154	63.44	1.17	0.009
25–29.9	8080	7167	5488	88.70	1.05	0.077	67.92	1.15	0.020	2592	68.36	1.18	0.006
30+	4802	4369	3312	90.98	1.06	0.046	68.97	1.16	0.013	1490	74.30	1.20	0.003
Missing	800	652	511	81.50	0.98	0.515	63.88	1.18	0.017	289	52.25	0.95	0.498
NCDs in history
No	13 888	11 958	8688	86.10	1.00	–	62.56	1.00	–	5200	65.23	1.00	–
Yes	7152	6500	5161	90.88	1.00	0.818	72.16	1.06	<0.001	1991	71.97	1.00	0.813
Missing	1090	891	634	81.74	1.02	0.266	58.17	0.91	0.002	456	59.21	1.12	0.005
Vaccination
Vaccination—no	7647	5095	0	66.63	1.00	–	0.00
Vaccination—yes	14 483	14 254	14 483	98.42	1.52	<0.001	100.00
Total	22 130	19 349	14 483							7647

Seronegative=participants who were seronegative in the first phase of the study; seropositive—no symptoms=participants who were seropositive in the first phase of the study and did not suffer from the selected symptoms (temperature >37.5°C, cough, shortness of breath, loss of taste or olfactory sense, faintness); seropositive—with symptoms=participants who were seropositive in the first phase of the study and suffer from the selected symptoms (temperature >37.5°C, cough, shortness of breath, loss of taste or olfactory sense, faintness); NCDs in history=participant indicated that suffer from one or more from the following disorders (diabetes, hypertension, lung diseases (asthma, chronic obstructive pulmonary disease); vaccination—no=participant was not vaccinated against SARS-CoV-2 regardless of vaccine type or dose; vaccination—yes=participant was vaccinated against SARS-CoV-2 regardless of vaccine type or dose.
BMI, body mass index; NCD, non-communicable disease; PRR, prevalence rate ratio.